These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25282704)

  • 1. Long-term follow-up of TaG1 non-muscle-invasive bladder cancer.
    Olivier Bosset P; Neuzillet Y; Paoletti X; Molinie V; Botto H; Lebret T
    Urol Oncol; 2015 Jan; 33(1):20.e1-20.e7. PubMed ID: 25282704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Holmäng S; Babjuk M; Fajkovic H; Seitz C; Klatte T; Pycha A; Bachmann A; Scherr DS; Shariat SF
    Eur Urol; 2014 Jan; 65(1):201-9. PubMed ID: 23998688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.
    Ofude M; Kitagawa Y; Yaegashi H; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):161-8. PubMed ID: 25108407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.
    von Landenberg N; Aziz A; von Rundstedt FC; Dobruch J; Kluth LA; Necchi A; Noon A; Rink M; Hendricksen K; Decaestecker KPJ; Seiler R; Poyet C; Fajkovic H; Shariat SF; Xylinas E; Roghmann F;
    Urol Oncol; 2018 May; 36(5):238.e19-238.e27. PubMed ID: 29506940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
    Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
    World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?
    Busato Júnior WF; Almeida GL; Ribas CA; Ribas Filho JM; De Cobelli O
    Clin Genitourin Cancer; 2016 Apr; 14(2):176-82. PubMed ID: 26444918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Soria F; Moschini M; Abufaraj M; Wirth GJ; Foerster B; Gust KM; Özsoy M; Briganti A; Gontero P; Mathieu R; Rouprêt M; Karakiewicz PI; Shariat SF
    Urol Oncol; 2017 Mar; 35(3):113.e9-113.e14. PubMed ID: 27908681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
    Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
    Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
    Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    Zhang G; Steinbach D; Grimm MO; Horstmann M
    World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
    Xylinas E; Kent M; Dabi Y; Rieken M; Kluth LA; Al Hussein Al Awamlh B; Ouzaid I; Pycha A; Comploj E; Svatek RS; Lotan Y; Karakiewicz PI; Holmang S; Shariat SF
    Urol Oncol; 2018 Mar; 36(3):89.e1-89.e5. PubMed ID: 29221642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.